JANX Stock Price, Janux Therapeutics, Inc. Quote, Chart

Market Summary

USD48.04-1.74

Delayedas of 24 Apr 2024, 03:01 pm

-3.50%

JANX Stock Price

View Fullscreen

JANX RSI Chart

JANX Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

-44.12

Price/Sales (Trailing)

159.09

Price/Free Cashflow

-49.05

JANX Price/Sales (Trailing)

JANX Profitability

Return on Equity

-16.93%

Return on Assets

-15.32%

Free Cashflow Yield

-2.04%

JANX Fundamentals

JANX Revenue

Revenue (TTM)

16.2M

Rev. Growth (Yr)

342.56%

Rev. Growth (Qtr)

201.37%

JANX Earnings

Earnings (TTM)

-58.3M

Earnings Growth (Yr)

26.81%

Earnings Growth (Qtr)

-1.64%

Breaking Down JANX Revenue

52 Week Range

9.1950.06

(Low)(High)

Last 7 days

-1.3%

Last 30 days

26.3%

Last 90 days

432.7%

Trailing 12 Months

231.8%

How does JANX drawdown profile look like?

JANX Financial Health

Current Ratio

26.8

JANX Investor Care

Shares Dilution (1Y)

10.81%

Diluted EPS (TTM)

-1.33

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	6.7M	9.6M	10.3M	16.2M
2022	3.4M	3.3M	3.9M	4.0M
2021	0	0	0	3.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Janux Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 29, 2024	avalon ventures xi, l.p.	sold	-	-	-438,722	-
Feb 29, 2024	avalon ventures xi, l.p.	acquired	-	-	31,456	-
Feb 29, 2024	avalon ventures xi, l.p.	sold	-	-	-31,456	-
Feb 29, 2024	avalon ventures xi, l.p.	acquired	-	-	1,700	-
Feb 29, 2024	avalon ventures xi, l.p.	sold	-	-	-1,700	-
Feb 29, 2024	avalon ventures xi, l.p.	sold	-	-	-84,985	-
Feb 29, 2024	avalon ventures xi, l.p.	sold	-	-	-447,949	-
Feb 29, 2024	avalon ventures xi, l.p.	acquired	-	-	11,388	-
Feb 29, 2024	avalon ventures xi, l.p.	sold	-	-	-11,388	-
Feb 29, 2024	gujrathi sheila	acquired	-	-	2,986	-

Which funds bought or sold JANX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	6,899	113,888	-%
Apr 19, 2024	Cutler Group LLC / CA	new	-	15,000	15,000	-%
Apr 18, 2024	McGlone Suttner Wealth Management, Inc.	sold off	-	-	-	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	reduced	-75.83	-42,772	239,040	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	reduced	-46.89	131,623	284,032	0.01%
Apr 11, 2024	Fortitude Family Office, LLC	reduced	-12.66	5,251	7,794	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Apr 05, 2024	GAMMA Investing LLC	new	-	678	678	-%
Mar 11, 2024	VANGUARD GROUP INC	added	3.95	1,011,660	10,509,900	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	449	710,680	857,284	-%

Are Funds Buying or Selling JANX?

Are funds buying JANX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own JANX

No. of Funds

Unveiling Janux Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 06, 2024	ra capital management, l.p.	19.99%	10,593,395	SC 13D/A
Mar 04, 2024	avalon ventures xi, l.p.	7.7%	3,948,495	SC 13D/A
Feb 14, 2024	biotechnology value fund l p	5.3%	2,427,414	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	0%	0	SC 13G/A
Feb 14, 2024	citadel advisors llc	6.8%	6	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	campbell david alan	5.3%	2,545,075	SC 13G/A
Feb 01, 2024	bregua corp	8.3%	3,830,257	SC 13G/A
Nov 16, 2023	avalon ventures xi, l.p.	9.5%	4,387,217	SC 13D/A
Jul 10, 2023	citadel advisors llc	4.9%	6	SC 13G

Recent SEC filings of Janux Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Mar 08, 2024	10-K	Annual Report
Mar 08, 2024	8-K	Current Report
Mar 08, 2024	S-8	Employee Benefits Plan
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	SC 13D/A	13D - Major Acquisition
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	SC 13D/A	13D - Major Acquisition
Feb 29, 2024	8-K	Current Report

Peers (Alternatives to Janux Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Janux Therapeutics, Inc. News

Latest updates

Janux Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)												(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	201.4%	7,586	2,517	3,240	2,822	1,714	1,813	373	132	1,616	1,159	482	380
Operating Expenses	1.5%	18,598	18,330	21,805	22,329	21,111	19,835	19,626	15,131	15,106	12,062	6,734	2,664
S&GA Expenses	-1.3%	6,357	6,438	6,881	6,464	5,677	6,098	5,540	4,947	3,937	3,656	1,997	739
R&D Expenses	2.9%	12,241	11,892	14,924	15,865	15,434	13,737	14,086	10,184	11,169	8,406	4,737	1,925
Net Income	-1.6%	-11,758	-11,568	-17,508	-17,459	-16,065	-16,696	-16,888	-13,410	-13,416	-10,766	-6,206	-2,284
Net Income Margin	24.3%	-3.61*	-4.76*	-5.44*	-7.01*	-9.16*	-15.36*	-16.61*	-12.92*	-8.98*	-	-	-
Free Cashflow	14.5%	-10,416	-12,179	-15,634	-14,196	-13,969	-15,934	-6,971	-12,493	-11,654	-5,931	-6,283	5,410

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-1.7%	380	387	342	353	364	376	385	369	380	391	397	-
Current Assets	-1.7%	349	355	309	321	332	344	358	365	377	390	397	16.00
Cash Equivalents	12.0%	19.00	17.00	34.00	30.00	51.00	65.00	58.00	55.00	36.00	39.00	252	8.00
Net PPE	-4.3%	7.00	7.00	7.00	7.00	7.00	7.00	4.00	3.00	1.00	1.00	0.00	0.00
Liabilities	-4.9%	36.00	38.00	42.00	42.00	43.00	44.00	42.00	13.00	13.00	14.00	12.00	9.00
Current Liabilities	-9.9%	13.00	14.00	18.00	16.00	17.00	16.00	13.00	13.00	13.00	12.00	9.00	3.00
Shareholder's Equity	-1.3%	344	349	299	311	321	332	344	356	366	377	385	-
Retained Earnings	-7.5%	-168	-157	-145	-127	-110	-94.40	-77.71	-60.82	-47.41	-34.00	-23.23	-14.74
Additional Paid-In Capital	1.0%	512	507	446	440	433	428	423	418	414	411	408	0.00
Shares Outstanding	0.2%	46.00	46.00	42.00	42.00	42.00	41.00	41.00	41.00	41.00	18.00	10.00	1.00
Float	-	-	-	280	-	-	-	205	-	-	-	526	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	15.4%	-9,901	-11,709	-15,054	-13,911	-11,913	-13,414	-6,073	-11,522	-10,481	-5,854	-6,204	5,563	-	-	-
Share Based Compensation	-1.4%	4,483	4,548	5,501	5,473	4,205	4,596	4,444	3,958	2,944	2,566	1,277	123	-	28.00	2.00
Cashflow From Investing	118.1%	11,123	-61,451	17,874	-8,740	-1,604	19,763	9,039	31,068	7,326	-205,539	-142,597	-153	-	-	-
Cashflow From Financing	-98.5%	831	56,609	528	1,580	191	-	308	1.00	164	-843	329,657	57,546	-	-	-

JANX Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Collaboration revenue	$ 8,083	$ 8,612
Operating expenses:
Research and development	54,922	53,441
General and administrative	26,140	22,262
Total operating expenses	81,062	75,703
Loss from operations	(72,979)	(67,091)
Other income:
Interest income	14,686	4,032
Total other income	14,686	4,032
Net loss	(58,293)	(63,059)
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities, net	2,200	(1,265)
Comprehensive loss	$ (56,093)	$ (64,324)
Net loss per common share, basic	$ (1.32)	$ (1.52)
Net loss per common share, diluted	$ (1.32)	$ (1.52)
Weighted-average shares of common stock outstanding, basic	44,016,283	41,469,631
Weighted-average shares of common stock outstanding diluted	44,016,283	41,469,631

JANX Balance Sheet

2023-12-31

Condensed Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 19,205	$ 51,426
Short-term investments	324,823	275,590
Prepaid expenses and other current assets	5,213	5,423
Total current assets	349,241	332,439
Restricted cash	816	816
Property and equipment, net	7,003	7,086
Operating lease right-of-use assets	20,838	22,279
Other long-term assets	2,509	1,390
Total assets	380,407	364,010
Current liabilities:
Accounts payable	2,424	2,159
Accrued expenses	7,387	8,179
Current portion of deferred revenue	1,705	5,406
Current portion of operating lease liabilities	1,517	763
Total current liabilities	13,033	16,507
Deferred revenue, net of current portion	0	2,221
Operating lease liabilities, net of current portion	23,025	24,542
Total liabilities	36,058	43,270
Commitments and contingencies (Note 3)
Stockholders’ equity (deficit):
Preferred stock, $0.001 par value; authorized shares - 10,000,000 at December 31, 2023 and 2022, respectively; no shares issued and outstanding at December 31, 2023 and 2022
Common stock, $0.001 par value; authorized shares - 200,000,000 at December 31, 2023 and 2022, respectively; issued shares - 46,262,759 and 41,684,666 at December 31, 2023 and 2022, respectively; outstanding shares - 46,252,440 and 41,616,260 at December 31, 2023 and 2022, respectively	46	42
Additional paid-in capital	512,401	432,703
Accumulated other comprehensive income (loss)	665	(1,535)
Accumulated deficit	(168,763)	(110,470)
Total stockholders' equity	344,349	320,740
Total liabilities and stockholders' equity	$ 380,407	$ 364,010

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.

CEO	Dr. David Alan Campbell Ph.D.
WEBSITE	januxrx.com
INDUSTRY	Biotechnology
EMPLOYEES	67

Janux Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Janux Therapeutics, Inc.? What does JANX stand for in stocks?

JANX is the stock ticker symbol of Janux Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Janux Therapeutics, Inc. (JANX)?

As of Tue Apr 23 2024, market cap of Janux Therapeutics, Inc. is 2.57 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JANX stock?

You can check JANX's fair value in chart for subscribers.

What is the fair value of JANX stock?

You can check JANX's fair value in chart for subscribers. The fair value of Janux Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Janux Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for JANX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Janux Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether JANX is over valued or under valued. Whether Janux Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Janux Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JANX.

What is Janux Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, JANX's PE ratio (Price to Earnings) is -44.12 and Price to Sales (PS) ratio is 159.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JANX PE ratio will change depending on the future growth rate expectations of investors.